Martin Gouldstone
Patrimonio netto: 5 179 $ in data 31/05/2026
Patrimonio netto: 5 179 $ in data 31/05/2026
Martin John Gouldstone is Chief Executive Officer & Director at Oncimmune Holdings Plc since 2023.
He is Chief Executive Officer at Oncimmune Germany.
GmbH.
He is Independent Non-Executive Chairman at ValiRx Plc since 2024.
He is Independent Non-Executive Director at hVIVO Holdings Ltd. since 2022.
Former roles include Independent Non-Executive Director at hVIVO PLC from 2022 to 2025.
Director at Novara Therapeutics Ltd. Director-Corporate Advisory & Head-Life Sciences at BDO UK LLP from 2015 to 2017.
Director-Business Development at Sareum Ltd. from 2006 to 2008.
Director at Orthopaedic Research UK from 2019 to 2024.
Partner at Results Healthcare from 2017 to 2018.
Chief Business Development Officer at Arcturis Data Ltd. from 2021 to 2022.
Global Senior Vice President-Business Development at Owkin, Inc. Chief Business Officer at BenevolentAI SA from 2018 to 2019.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
VALIRX PLC 0,27% | 21/11/2025 | 1.969.231 ( 0,27% ) | 5 179 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ONCE HLDG | Amministratore Delegato | 01/08/2023 |
| HVIVO PLC | Direttore/Membro del Consiglio | 01/06/2022 |
| VALIRX PLC | Presidente | 25/07/2024 |
Oncimmune Germany GmbH
Oncimmune Germany GmbH BiotechnologyHealth Technology Develops antibody and autoantibody biomarker discovery platform | Amministratore Delegato | - |
| Società | Posizione | Fine |
|---|---|---|
| HVIVO PLC | Direttore/Membro del Consiglio | 05/06/2025 |
Orthopaedic Research UK
Orthopaedic Research UK Miscellaneous Commercial ServicesCommercial Services Provides business support services | Direttore/Membro del Consiglio | 01/03/2024 |
| SENSYNE HEALTH PLC | Corporate Officer/Principal | 01/05/2022 |
| BENEVOLENTAI S.A. | Corporate Officer/Principal | 01/01/2019 |
Results Healthcare
Results Healthcare Investment ManagersFinance Provides advisory services | Corporate Officer/Principal | 01/06/2018 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 12 |
|---|---|
ValiRx Plc
ValiRx Plc Pharmaceuticals: MajorHealth Technology Develops novel technologies and products in oncology therapeutics and diagnostics | Health Technology |
hVIVO Holdings Ltd.
hVIVO Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Provides medical research services | Commercial Services |
Sareum Ltd.
Sareum Ltd. Drugstore ChainsRetail Trade Provides drug discovery services | Retail Trade |
Results Healthcare
Results Healthcare Investment ManagersFinance Provides advisory services | Finance |
Oncimmune Holdings Plc
Oncimmune Holdings Plc BiotechnologyHealth Technology Provides cancer detection and diagnosis services | Health Technology |
Orthopaedic Research UK
Orthopaedic Research UK Miscellaneous Commercial ServicesCommercial Services Provides business support services | Commercial Services |
Owkin, Inc.
Owkin, Inc. Packaged SoftwareTechnology Services Develops AI technology that accelerates drug discovery by combining multimodal patient data and large language models | Technology Services |
Sensyne Health Ltd.
Sensyne Health Ltd. Miscellaneous Commercial ServicesCommercial Services Provides statistical analyses and advanced insights to the healthcare industry | Commercial Services |
BDO UK LLP
BDO UK LLP Miscellaneous Commercial ServicesCommercial Services Provides tax, audit & assurance, advisory and business outsourcing services | Commercial Services |
hVIVO PLC
hVIVO PLC Miscellaneous Commercial ServicesCommercial Services Provides pharmaceutical development services | Commercial Services |
Oncimmune Germany GmbH
Oncimmune Germany GmbH BiotechnologyHealth Technology Develops antibody and autoantibody biomarker discovery platform | Health Technology |
BenevolentAI SA
BenevolentAI SA Packaged SoftwareTechnology Services Develops AI drug discovery platform to accelerate biopharma drug discovery | Technology Services |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale